Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.17.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Oncosem Onkolojik Sistemlernayi ve Ticaret AScouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
IST:ONCSM's Cash-to-Debt is ranked worse than 85.95% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs IST:ONCSM: 0.17
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Cash-to-Debt Related Terms
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Cash-to-Debt Chart
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
IST:ONCSM vs ABT, SYK, MDT: Cash-to-Debt Comparison
For the Medical Devices subindustry, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Cash-to-Debt vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a Cash-to-Debt of 0.17 as of Jun. 2026. This is 76% below median its historical median of 0.70. Over the past decade, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Cash-to-Debt has ranged from 0.17 to 3.28. According to the industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #722 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 86%.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Cash-to-Debt too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Cash-to-Debt of 0.17 is 76% below median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 3.28. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 0.17 is 89.6% below this industry median. Based on the distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #722 out of 840 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #722 out of 840 companies for Cash-to-Debt. This places Oncosem Onkolojik Sistemlernayi ve Ticaret AS in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 0.17 is 89.6% below this benchmark. Historically, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's own Cash-to-Debt has ranged from 0.17 to 3.28 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 1.64, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Cash-to-Debt of 0.17 is 89.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Cash-to-Debt is 0.17, which is 76% below median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₺270.29, compared to a current price of ₺196.40 — trading 27.3% below its estimated fair value. The current Cash-to-Debt is 0.17, which is 76% below median its 10-year median of 0.70 and 89.6% below the Medical Devices & Instruments industry median of 1.64. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current Cash-to-Debt is 0.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be undervalued.
The current stock price of ₺196.40 is trading 27.3% below its estimated GF Value™ of ₺270.29.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Modestly Undervalued.
Key valuation signals for IST:ONCSM:
Cash-to-Debt: 0.17 (76% below median its 10-year median of 0.70)
GF Value™: ₺270.29 vs. price of ₺196.40 (27.3% below fair value)
Industry Position: 89.6% below the Medical Devices & Instruments median (#722 of 840)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
